Weekly roundup: Approvals, AI breakthroughs, and patient care innovations
Biocomposites announced expanded approval in India for STIMULAN® Rapid Cure to be mixed with antimicrobials to treat infection
Biocomposites announces the expanded approval for STIMULAN® Rapid Cure in India. The approval from India’s Central Drugs Standard Control Organisation (CDSCO) allows STIMULAN® Rapid Cure to be mixed with a wider variety of antibiotics than before, including in combination, and also with antifungals, to assist in wound healing and treatment of infection.
Neuraxpharm and mjn-neuro announced plans to launch a digital health solution using an AI-powered wearable device for the early detection of epileptic seizures
Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, and mjn-neuro, a start-up that designs, manufactures and markets medical devices, announced the upcoming launch of a pioneering digital health solution designed to predict the risk of epileptic seizures in real time.
📺Optimum TV
Watch our latest episode of Optimum TV, where Paulo Neves, Chief Medical Officer of Xeltis, discusses the company’s recent announcement of successful clinical data from the EU pivotal trial of aXess, its restorative vascular access conduit.
Xeltis is developing transformative implants that regenerate the patient’s own tissue before gradually being absorbed and leaving new, living, and long-lasting vessels in place. aXess delivered major improvements on all key clinical metrics compared to the standard of care, demonstrating its transformative potential in hemodialysis treatment.
🔥Hot topic
Online pharmacies and the arrival of GLP-1 weight loss drugs have resulted in the emergence of a powerful new trend: people ‘self-paying’ for prescription drugs. What is the opportunity for pharma companies and what happens from here? Read our insightful weekly hot topic here ⬇️
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
